David A. Siegel Cardiff Oncology, Inc. Transaction History

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 205,600 shares of CRDF stock, worth $499,608. This represents 0.0% of its overall portfolio holdings.

Number of Shares

205,600

Previous 17,500 1074.86%

Holding current value

$499,608

Previous $54,000 1098.15%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$2.38 - $4.3 $447,678 - $808,830	188,100 Added 1074.86%	205,600 $647,000
Q1 2025 May 15, 2025	BUY	$3.14 - $4.75 $8,478 - $12,825	2,700 Added 18.24%	17,500 $54,000
Q4 2024 Feb 14, 2025	SELL	$2.31 - $5.35 $730,884 - $1.69 Million	-316,400 Reduced 95.53%	14,800 $64,000
Q3 2024 Nov 14, 2024	BUY	$2.05 - $2.77 $254,609 - $344,034	124,200 Added 60.0%	331,200 $884,000
Q2 2024 Aug 14, 2024	BUY	$2.22 - $5.89 $411,366 - $1.09 Million	185,300 Added 853.92%	207,000 $459,000
Q1 2024 May 15, 2024	SELL	$1.46 - $5.91 $25,550 - $103,425	-17,500 Reduced 44.64%	21,700 $115,000
Q4 2023 Feb 14, 2024	SELL	$0.96 - $1.55 $1,728 - $2,790	-1,800 Reduced 4.39%	39,200 $58,000
Q3 2023 Nov 14, 2023	SELL	$1.38 - $2.18 $181,884 - $287,324	-131,800 Reduced 76.27%	41,000 $56,000
Q2 2023 Aug 14, 2023	BUY	$1.37 - $1.95 $40,141 - $57,135	29,300 Added 20.42%	172,800 $254,000
Q1 2023 May 15, 2023	SELL	$1.45 - $2.09 $62,930 - $90,706	-43,400 Reduced 23.22%	143,500 $236,000
Q4 2022 Feb 14, 2023	SELL	$1.22 - $1.66 $11,712 - $15,936	-9,600 Reduced 4.89%	186,900 $261,000
Q3 2022 Nov 14, 2022	SELL	$1.54 - $3.21 $212,982 - $443,943	-138,300 Reduced 41.31%	196,500 $303,000
Q2 2022 Aug 15, 2022	SELL	$1.17 - $2.61 $209,781 - $467,973	-179,300 Reduced 34.88%	334,800 $737,000
Q1 2022 May 16, 2022	SELL	$2.11 - $7.25 $318,399 - $1.09 Million	-150,900 Reduced 22.69%	514,100 $1.28 Million
Q4 2021 Feb 14, 2022	SELL	$5.18 - $7.24 $185,444 - $259,192	-35,800 Reduced 5.11%	665,000 $4 Million
Q3 2021 Nov 15, 2021	BUY	$5.01 - $7.58 $178,356 - $269,848	35,600 Added 5.35%	700,800 $4.67 Million
Q2 2021 Aug 16, 2021	BUY	$6.65 - $10.04 $527,345 - $796,171	79,300 Added 13.53%	665,200 $4.42 Million
Q1 2021 May 17, 2021	BUY	$9.1 - $19.57 $4.26 Million - $9.15 Million	467,600 Added 395.27%	585,900 $5.43 Million
Q4 2020 Feb 16, 2021	BUY	$12.02 - $24.71 $1.42 Million - $2.92 Million	118,300 New	118,300 $2.13 Million

Others Institutions Holding CRDF

# of Institutions

125

Shares Held

25.8M

Call Options Held

978K

Put Options Held

295K

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $105M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account